Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection
Clinical trial NCT03839550 · UNKNOWN
Trial details
- NCT number
- NCT03839550
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-15
- Primary completion
- 2020-02-28
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.